New hope for lymphoma patients: first test of novel drug combo
NCT ID NCT06139406
Summary
This is the first human study of an experimental drug called JNJ-87801493, given alongside other drugs that help the immune system fight cancer. The main goal is to find a safe dose and understand the side effects in 70 adults with B-cell non-Hodgkin lymphoma that has returned or not responded to other treatments. Researchers will also look for early signs that the treatment might help control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA, NON-HODGKIN are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Austin Hospital
Heidelberg, 3084, Australia
-
Clinica Univ. de Navarra
Pamplona, 31008, Spain
-
Hadassah Medical Center
Jerusalem, 9112001, Israel
-
Hosp Clinico Univ de Salamanca
Salamanca, 37007, Spain
-
Hosp Univ Fund Jimenez Diaz
Madrid, 28040, Spain
-
Hosp Univ Vall D Hebron
Barcelona, 08035, Spain
-
Linear Clinical Research Ltd
Nedlands, 6009, Australia
-
Odense University Hospital
Odense, 5000, Denmark
-
Rigshospitalet
Copenhagen, DK-2100, Denmark
-
Scientia Clinical Research
Randwick, 2031, Australia
-
Sourasky (Ichilov) Medical Center
Tel Aviv, 6423906, Israel
-
The Alfred Hospital
Melbourne, 3004, Australia
Conditions
Explore the condition pages connected to this study.